ORMP Oramed Pharmaceuticals Inc

Price (delayed)

$4.38

Market cap

$182.2M

P/E Ratio

1.04

Dividend/share

$0.25

EPS

$4.23

Enterprise value

$167.68M

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 63

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a diversified operating company that deploys capital across the biomedical and broader investment landscape, leveraging deep industry relationships, regulatory expertise, and operational experience to ...

Highlights
The equity has soared by 105% YoY and by 33% from the previous quarter
The EPS has surged by 60% since the previous quarter
The gross profit has plunged by 100% YoY
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of ORMP

ORMP stock price

How has the Oramed Pharmaceuticals stock price performed over time
Intraday
2.58%
1 week
1.86%
1 month
10.75%
1 year
106.6%
YTD
53.68%
QTD
-8.94%

Financial performance

How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.52M
Net income
$174.87M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 100% YoY
The revenue has dropped by 100% year-on-year
The net income has soared by 59% QoQ
The operating income has declined by 6% year-on-year

Price vs fundamentals

How does ORMP's price correlate with its fundamentals

Growth

What is Oramed Pharmaceuticals's growth rate over time

Valuation

What is Oramed Pharmaceuticals stock price valuation
P/E
1.04
P/B
0.56
P/S
N/A
EV/EBIT
1.44
EV/EBITDA
1.44
EV/Sales
N/A
The EPS has surged by 60% since the previous quarter
The price to earnings (P/E) is 39% lower than the last 4 quarters average of 1.7
The equity has soared by 105% YoY and by 33% from the previous quarter
The P/B is 57% less than the 5-year quarterly average of 1.3 and 7% less than the last 4 quarters average of 0.6
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Oramed Pharmaceuticals business performance
The ROE has grown by 32% from the previous quarter
The ROA is up by 29% since the previous quarter
The company's return on invested capital fell by 22% QoQ

Dividends

What is ORMP's dividend history
DPS
$0.25
Dividend yield
5.71%
Payout ratio
5.9%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Oramed Pharmaceuticals financials performed over time
The total assets has soared by 129% YoY and by 37% from the previous quarter
Oramed Pharmaceuticals's quick ratio has shrunk by 82% YoY and by 23% QoQ
ORMP's debt is 100% lower than its equity
The equity has soared by 105% YoY and by 33% from the previous quarter
Oramed Pharmaceuticals's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.